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Human chorionic gonadotropin (hCG) is useful in evaluating andmonitoring early pregnancy as well as trophoblastic disease. Here
we describe the management of women with elevated serum human chorionic gonadotropin in a case of a 51-year-old female who
was unsuccessfully treated for ectopic pregnancy. She was subsequently diagnosed with pituitary hCG production, which should
be considered as differential diagnosis before treatment is initiated.
1. Short Communication
A 51-year-old parous woman presented with a history of
intermittent pelvic cramps and vaginal spotting after two
years of amenorrhoea following insertion of an etonogestrel
implant for contraception. She was found to have an elevated
serum human chorionic gonadotropin (total 𝛽 hCG (hCG
+ hCG𝛽)) measured via a quantitative electrochemilumines-
cence immunoassay “ECLIA” recognizing the holo-hormone,
“nicked” forms of hCG, the 𝛽-core fragment, and the free 𝛽-
subunit (Elecsys free 𝛽-hCG, Roche Diagnostics, Germany).
Several measurements were performed and total 𝛽 hCG
levels of 16.2 to 32.8 IU/L were detected. To exclude a missed
abortion, dilatation and curettage were done but the his-
tology excluded any pregnancy products showing secretory
endometrium and a benign endometrial polyp. Ectopic preg-
nancy or gestational trophoblastic disease (GTD) was not
identified by subsequent CT scans [1]. To exclude phantom
or false positive hCG results caused by unspecific binding of
heterophilic serum antibodies, urine hCG was measured and
found to be positive [2]. Furthermore heterophilic blocking
tube (Scantibodies Laboratory, Inc., USA) pretreatment of the
serum samples was performed, and the results were the same
as in the original assay [3].
As the clinical picture was consistent with an uniden-
tified ectopic pregnancy, the patient was commenced on
methotrexate 50mg/m2 intramuscularly [4]. However, the
serum total 𝛽 hCG remained elevated.
As pregnancy, GTD, and ovarian neoplasia had been
excluded, another differential diagnosis was pituitary hCG
production [5]. The patient’s hormone status was therefore
assessed and a follicular stimulating hormone (FSH) of
60.2U/L (reference intervals: follicular phase 3.5–12.5U/L,
luteal phase 1.5–8.0U/L, postmenopausal 25–135U/L)
showed postmenopausal levels [6]. To suppress pituitary
hCG production the patient was placed on a combined
oestrogen-progesterone hormone replacement therapy and
after two weeks the serum hCG levels were found to be
normal, measuring <2.0 IU/L on serial testing.
2. Discussion
Human chorionic gonadotropin (hCG) is a heterodimeric
glycoprotein hormone composed of an 𝛼-chain (hCG𝛼) and
a 𝛽-chain (hCG𝛽). hCG𝛼 is essentially identical to that
of luteinizing hormone (LH), follicle-stimulating hormone
(FSH), and thyroid-stimulating hormone (TSH), whereas the
𝛽-chains have greatly differing structures and are responsible
for the respective specific hormonal functions and immuno-
logical specificity [7]. In pregnancy, intact hCG is the most
common form and free hCG𝛽 accounts for less than 1%
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Figure 1: Algorithm for interpreting low serum hCG results in
perimenopausal women to exclude pituitary hCG production.
of total 𝛽 hCG (hCG + hCG𝛽) in serum [8]. Apart from
pregnancy, there are other gynaecological conditions that can
cause an elevated serum hCG. Gestational trophoblastic dis-
eases such as hydatidiform moles, gestational trophoblastic
neoplasias, and choriocarcinomas are diseases where hCG
is elevated and the hCG ratio changes in favour of free
hCG𝛽 [9]. Other gynaecological malignancies with elevated
hCG include placental site trophoblastic tumours and ovarian
germ cell tumors [10].
False-positive results mimicking disease can be related to
the assays used to detect hCG. In some tests cross-reactions
with other serum glycoproteins results in false-positive hCG
levels. Furthermore heterophilic serum antibodies (e.g., anti-
mouse antibodies) can bind nonspecifically to antibodies
used in the hCG assays, therefore, resulting in false-positive
levels [11]. Conversely, a false-negative resultmay be the result
of a hook effect when very high levels of hCG𝛽 supersaturate
the antibodies in the assay and result in false low levels [12].
In gestational trophoblastic neoplasia, aberrant glyco-
sylation and overexpression of the hCG𝛽 result in hyper-
glycosylated hCG. Hyperglycosylated hCG shares the same
polypeptide structure as hCGbutwith largerN- andO-linked
oligosaccharides. It promotes growth of cytotrophoblast cells
and placental implantation in pregnancy aswell as invasion of
the trophoblast in gestational trophoblastic neoplasia [13, 14].
Although gynaecological malignancies are a common
reason for elevated serum hCG in nonpregnant women,
it has also been described as paraneoplastic syndrome in
other nongynaecological malignancies including cancers of
the bladder, kidney, prostate, GI-tract, breast, and lung [10].
Another potential origin of hCG production which is
sometimes overlooked due to the common focus on ectopic
pregnancy or an underlyingmalignancy is the pituitary gland
in peri- or postmenopausal women [15]. The exact mecha-
nism of hCG production in the gonadotropic cells of peri-
or postmenopausal women or after bilateral oophorectomy
is unknown. The most likely explanation is the reduction
of ovarian steroid hormone synthesis that releases the neg-
ative feedback control of gonadotropin-releasing hormone
(GnRH). Under this overstimulation, the pituitary may
secrete hCG [5].
The presented case shows that there is often an incorrect
assumption in themedical community that an elevated serum
hCG implies that a patient is pregnant or has a trophoblastic
disease. Ultimately this resulted in our case in unnecessary
and potentially harmful therapy, which could have been easily
avoided. Low levels of HCG can be a normal physiological
phenomenon in peri- and postmenopausal women. Pituitary
hCG is more commonly detected in women greater than 55
years of age but can be detected in women as young as 41
years. Pituitary hCG therefore needs to be excluded in peri-
or postmenopausal women (Figure 1).
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